Analysts expect that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will post earnings per share of ($1.00) for the current quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.67). Nektar Therapeutics posted earnings of ($0.69) per […]
New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced bladder
Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will report $23.05 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $26.60 million and the lowest is $21.29 million. Nektar Therapeutics reported sales of $28.33 million during the […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.